Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$48.64 +2.4%	$39.69	$30.04 ▼ $63.68	$4.10B	1.75	1.86 million shs	5.28 million shs
DNA Ginkgo Bioworks	$11.29 +19.3%	$7.97	$5.00 ▼ $16.85	$553.71M	1.25	1.43 million shs	2.79 million shs
HIMS Hims & Hers Health	$49.94 +1.1%	$50.57	$13.47 ▼ $72.98	$11.06B	2.09	23.06 million shs	36.43 million shs
TDOC Teladoc Health	$8.73 +3.8%	$7.23	$6.35 ▼ $15.21	$1.48B	1.78	6.32 million shs	7.89 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+2.42%	+6.78%	+34.96%	+46.77%	-9.94%
DNA Ginkgo Bioworks	+19.89%	+32.05%	+62.21%	+99.65%	-15.57%
HIMS Hims & Hers Health	+1.04%	+18.65%	-11.98%	+60.90%	+147.35%
TDOC Teladoc Health	+3.60%	+10.51%	+26.16%	+12.40%	-10.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.9283 of 5 stars	4.3	1.0	2.0	2.5	0.6
DNA Ginkgo Bioworks	0.8024 of 5 stars	0.8	2.0	1.8	2.5	1.3
HIMS Hims & Hers Health	2.0884 of 5 stars	2.0	2.0	1.7	3.3	1.9
TDOC Teladoc Health	2.0948 of 5 stars	2.2	4.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	47.51% Upside
DNA Ginkgo Bioworks	1.67	Reduce	$5.77	-48.92% Downside
HIMS Hims & Hers Health	1.92	Reduce	$39.58	-20.74% Downside
TDOC Teladoc Health	2.37	Hold	$9.60	9.93% Upside

Current Analyst Ratings Breakdown

Latest TDOC, HIMS, DNA, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/24/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00
6/23/2025	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
6/23/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
6/23/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/11/2025	HIMS Hims & Hers Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$40.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	112.59	N/A	N/A	$22.64 per share	2.15
DNA Ginkgo Bioworks	$227.04M	2.91	N/A	N/A	$13.17 per share	0.86
HIMS Hims & Hers Health	$1.48B	7.57	$0.36 per share	140.30	$2.16 per share	23.12
TDOC Teladoc Health	$2.57B	0.60	$5.78 per share	1.51	$8.66 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.69	72.38	96.04	1.86	9.24%	22.75%	15.51%	8/4/2025 (Estimated)
TDOC Teladoc Health	-$1.00B	-$5.92	N/A	N/A	N/A	-39.66%	-11.01%	-4.66%	7/30/2025 (Estimated)

Latest TDOC, HIMS, DNA, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/5/2025	Q1 2025	HIMS Hims & Hers Health	$0.12	$0.20	+$0.08	$0.20	$535.21 million	$586.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
DNA Ginkgo Bioworks	N/A	4.88	4.88
HIMS Hims & Hers Health	N/A	1.59	1.32
TDOC Teladoc Health	0.70	1.68	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
DNA Ginkgo Bioworks	78.63%
HIMS Hims & Hers Health	63.52%
TDOC Teladoc Health	76.82%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.10%
DNA Ginkgo Bioworks	9.72%
HIMS Hims & Hers Health	17.71%
TDOC Teladoc Health	0.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.82 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
HIMS Hims & Hers Health	650	223.83 million	184.19 million	Optionable
TDOC Teladoc Health	5,500	175.43 million	174.42 million	Optionable

TDOC, HIMS, DNA, and CRSP Headlines

Recent News About These Companies

UK Telehealth Market Insights and Strategy Forecast 2025-2034 Featuring Doctor Care Anywhere, Teladoc Health, Livi and Other Industry Leaders

2 hours ago | globenewswire.com

Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) Target Price at $9.60

June 29 at 2:31 AM | americanbankingnews.com

Zacks Research Cuts Earnings Estimates for Teladoc Health

June 27, 2025 | marketbeat.com

Teladoc Health to Face Bulk of Pixel Tracking, Data Sharing Suit

June 26, 2025 | news.bloomberglaw.comN

Teladoc Health, Inc. (NYSE:TDOC) Receives Average Recommendation of "Hold" from Analysts

June 26, 2025 | marketbeat.com

Teladoc Health (NYSE:TDOC) Stock Price Down 4.8% - What's Next?

June 25, 2025 | marketbeat.com

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?

June 24, 2025 | msn.com

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

June 24, 2025 | zacks.com

Teladoc Health (NYSE:TDOC) Sees Strong Trading Volume - Still a Buy?

June 24, 2025 | marketbeat.com

Here's why Teladoc Health stock price could surge 95%

June 24, 2025 | invezz.comI

Traders Buy High Volume of Teladoc Health Call Options (NYSE:TDOC)

June 24, 2025 | americanbankingnews.com

Teladoc (TDOC) Stock Trades Up, Here Is Why

June 23, 2025 | msn.com

Teladoc Health (NYSE:TDOC) Shares Up 6.8% - What's Next?

June 23, 2025 | marketbeat.com

Stock Traders Buy Large Volume of Teladoc Health Call Options (NYSE:TDOC)

June 23, 2025 | marketbeat.com

Teladoc (TDOC) Rises Higher Than Market: Key Facts

June 16, 2025 | zacks.com

Divita lays out Teladoc's M&A strategy in CEO's 2nd year

June 14, 2025 | fiercehealthcare.comF

Teladoc Health, Inc. (TDOC) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

June 11, 2025 | seekingalpha.com

Teladoc (TDOC) Outperforms Broader Market: What You Need to Know

June 9, 2025 | zacks.com

Omada Health: Helping Patients, Investors As Well?

June 7, 2025 | seekingalpha.com

Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Mackenzie Financial Corp

June 6, 2025 | marketbeat.com

Teladoc Health to Participate in Upcoming Investor Conference

June 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Hims & Hers Stock: Buy the Dip or Wait It Out?
By Gabriel Osorio-Mazilli | June 5, 2025
View Hims & Hers Stock: Buy the Dip or Wait It Out?
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
By Gabriel Osorio-Mazilli | June 24, 2025
View Why Hims & Hers Stock Could Be a Multi-Bagger in the Making

TDOC, HIMS, DNA, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$48.64 +1.15 (+2.42%)

As of 06/30/2025 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ginkgo Bioworks NYSE:DNA

$11.29 +1.83 (+19.34%)

As of 06/30/2025 03:58 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Hims & Hers Health NYSE:HIMS

$49.94 +0.53 (+1.07%)

As of 06/30/2025 03:58 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Teladoc Health NYSE:TDOC

$8.73 +0.32 (+3.80%)

As of 06/30/2025 03:58 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time